

2021 VIRTUAL MEETING

This promotional meeting is organised and funded by Kyowa Kirin.

WEDNESDAY 13th and THURSDAY 14th OCTOBER

This is a two-part meeting.

16:30 to 20:00

JOIN US at this two-part, interactive, virtual meeting and hear from leading experts in XLH on referral, differential diagnosis and treatment of XLH in children.

- Speak to practicing physicians from your country and around the world during interactive breakout sessions
- Ask questions and discuss topics with experts during the live Q&A sessions
- View and download materials to support management of XLH in children



MEETING CHAIR:

Professor Agnès Linglart, Professor of Paediatrics
Bicêtre Paris-Saclay Hospital, Le Kremlin-Bicêtre, France

OBJECTIVES OF THE MEETING:

- **Identify the key challenges** in optimally managing children with XLH and discuss how to address these in your centre
- Explore approaches to **encourage the earlier identification, referral and diagnosis** of children with XLH
- Provide practical advice on **how to optimise the treatment and management** of children with XLH
- **Share best practice to support multi-disciplinary team collaboration** to provide optimal care for children with XLH

XLH, X-Linked Hypophosphataemia



Register HERE

AGENDA | Day 1 - Patient identification, referral and diagnosis

Time: 16:30 – 20:00

Time	Session
16:30	WELCOME, INTRODUCTIONS AND OBJECTIVES
16:40	What are the causes and clinical impact of hypophosphataemia?
16:55	How to diagnose XLH in the metabolic disease landscape
17:10	How can we encourage earlier referral for better patient outcomes?
17:25	PANEL DISCUSSION: Optimising referral and early diagnosis Q&A
17:45	BREAK
18:00	WORKSHOP: Diagnosing XLH: Interactive case studies
18:45	WORKSHOP: What should the treatment goals be for children with XLH?
19:05	PANEL DISCUSSION AND SUMMARY: Ask the Experts
19:30 – 20:00	LOCAL WORKSHOP: Creating a local action plan to improve the identification and diagnosis of XLH

AGENDA | Day 2 - Treatment and multi-disciplinary team management of XLH

Time: 16:30 – 20:00

Time	Session
16:30	WELCOME, REVIEW OF DAY 1 AND OBJECTIVES
16:35	The patient's perspective (from XLH Alliance)
16:45	Achieving treatment goals for our patients
17:05	WORKSHOP: The practical use of CRYSVITA ▼ (burosumab)* in children with XLH to optimise outcomes
17:50	BREAK
18:05	Joining the dots: Co-ordinating the multi-disciplinary team – perspectives from different specialities
19:05	PANEL DISCUSSION AND SUMMARY: Ask the Experts
19:30 – 20:00	LOCAL WORKSHOP: Creating a local action plan to improve the management of XLH

Draft agenda subject to change.
Final agenda will be provided to registered attendees.

*CRYSVITA® is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and paediatric patients 1 year of age and older. | For full details please refer to the Israeli PI as approved by the MoH

Register HERE

XLH, X-Linked Hypophosphataemia | *CRYSVITA summary of product characteristics